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ZUSAMMENFASSUNG 
 
 
Tyrosinkinasen stellen eine Gruppe von Enzymen dar, die eine Schlüsselrolle in der 
Entstehung von Malignomen einnehmen. Sie agieren in zentralen Signaltransduk-
tionswegen mit weitreichendem Einfluss auf Proliferation, Differenzierung, Motilität 
und Apoptose von Zellen.  
Durch die enge Einbindung in mitogene Signalwege ist für die normale zelluläre 
Funktion eine exakte Regulation der Tyrosinkinaseexpression unausweichlich. Damit 
stehen Expressionsanalysen dieser Genfamilie derzeit im Fokus zahlreicher For-
schungsaktivitäten, die sich mit der molekularen Basis von Tumorentstehung und 
Tumorprogress befassen. Auch ist für zahlreiche Tumorentitäten, beispielsweise 
Mammakarzinome, nicht-kleinzellige Lungenkarzinome sowie gastrointestinale Stro-
matumoren, bereits eine Therapie mit Tyrosinkinaseinhibitoren gut etabliert. 
 
Basierend auf dem ersten nicht-redundanten Katalog von Tyrosinkinasen aus dem 
Jahre 2000 (Robinson et al., 2000) wurde in der vorliegenden Arbeit erstmals ein 
vollständiges Expressionsprofil aller Tyrosinkinasen im Prostatakarzinom erstellt. 
Dazu wurde die Expression von 89 Tyrosinkinasen mittels real-time PCR in gutarti-
gem und bösartigem Prostatagewebe untersucht. 
 
Ein hochstandardisiertes Verfahren zur Gewebegewinnung und –aufarbeitung, RNA-
Isolation sowie cDNA-Synthese wurde etabliert und eine Quantifizierung mittels eines 
real-time PCR Arrays (TaqMan Low Density Array, Applied Biosystems) durchge-
führt. Anschließend erfolgte die Zusammenstellung eines Auswertungsverfahrens für 
real-time PCR Daten, welches aktuelle Entwicklungen im Bereich der Normalisierung 
von Expressionsdaten berücksichtigt und aufgrund der hohen Genanzahl in hohem 
Maße automatisierbar ist. 
 
Dabei zeigten sich bei sechs Genen signifikante Expressionsunterschiede (ABL2: 
+3.46-fach, FGFR2: -3.46-fach, FGFR4: -4.59- fach, NTRK1: -4.38- fach, NTRK3: -
6.04- fach, ROR2: -3.765- fach; p=0,009-0,018).  
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Die Daten konnten für FGFR2 und ABL2 mit kommerziell verfügbaren Antikörpern 
immunhistochemisch verifiziert werden. 
Weitere Analysen müssen die Auswirkungen der beobachteten Expressionsunter-
schiede auf Proteinebene sowie einen möglichen prognostischen Wert der Daten 
klären. 
Die Ergebnisse verdeutlichen das Potential eines real-time PCR Arrays, welcher in 
der Lage ist, die Expression aller bekannten Tyrosinkinasen gleichzeitig zu quantifi-
zieren. Insbesondere die Überexpression von ABL2 stellt eine Entdeckung von gro-
ßem klinischem Interesse dar, da sie eine plausible molekulare Erklärung für die er-
folgreiche Anwendung des Tyrosinkinaseinhibitors Imatinib im Prostatakarzinom lie-
fert. 
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ABBREVIATIONS 
 
 
ADT Androgen deprivation therapy 
AR Androgen receptor 
ATP Adenosine triphosphate 
bp Base-pair 
BPH Benign prostatic hyperplasia 
CML Chronic myeloid leukaemia 
DRE Digital rectal examination 
G6PDH Glucose-6-phostphate-dehydrogenase 
GAPDH Glycerine-aldehyde-3-phosphate-dehydrogenase 
GIST Gastrointestinal stromal tumour 
HE 
HKG 
Hematoxylin-eosine 
Housekeeping gene 
HPRT1 Hypoxanthine-phosphoribosyltransferase 1 
LCM Laser-capture microdissection 
LN Lymphatical node 
PCA Adenocarcinoma of the prostate 
PSA Prostate-specific antigen 
RP Radical prostatectomy 
RT Reverse transcriptase 
SM Surgical margin 
SV Seminal vesicle 
TE Tris-EDTA 
TK Tyrosine kinase 
UBC Ubiquitin C 
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1. INTRODUCTION 
 
1.1. Prostate cancer 
Adenocarcinoma of the prostate (PCA) is the most frequent cancer and the second 
leading cause of cancer-related deaths in males in western industrialised countries. 
The mean age of onset is about 5 years higher than in other malignancies (71 years 
vs. 66 years), occurring before age of 50 is rarely found.  
Digital rectal examination (DRE) and level of prostate-specific antigen (PSA) are im-
portant indicators for early diagnosis, although autopsy studies and the Prostate 
Cancer Prevention Trial showed a higher prevalence of PCA than anticipated by PSA 
testing alone: incidental prostate carcinomas (with negative PSA and DRE) could be 
found in 29% of 30-40 years old and 64% of 60-70 years old men  (Sakr et al., 1994; 
Thompson et al., 2003). Therefore, gold standard in clinical diagnosis is still histopa-
thological examination (Routh and Leibovich, 2005), which is indicated when DRE is 
positive or PSA is >4 ng/ml. Since the introduction of PSA screening in the eighties 
the number of diagnosed PCA dramatically increased. This shows that there is a high 
number of asymptomatic tumours, the therapeutic relevance of which is unclear. 
Prostate carcinoma can be divided into three subcategories: 
a) Early carcinoma - organ confined 
b) Locally advanced PCA – infiltration of seminal vesicle or prostate capsule 
c) Metastatic PCA – metastases in lymph nodes or distant metastases 
 
Staging is performed according to the TNM-system (Table 1). 
 
 
 
 
 
 
 
   
11 
__________________________________________________________________________________________________________________________________________________________________ 
 
 
Table 1: TNM classification of prostate carcinoma 
 
Stage T1 Clinically inapparent tumour by palpation or imaging 
T1a Incidental histologic finding in ≤ 5% of resected tissue 
T1b Incidental histologic finding in ≥ 5% of resected tissue 
T1c Identification by needle biopsy 
Stage T2 Organ confined 
T2a ≤ 1/2 of one prostate lobe 
T2b ≥ 1/2 of one prostate lobe but not both lobes 
T2c Involves both lobes 
Stage T3 Extraprostatic extension 
T3a Extracapsular extension (uni- or bilateral) 
T3b Invasion of seminal vesicle 
Stage T4 Tumour fixed / invades adjacent structures (except seminal vesicle) 
 
Lymph nodes   
Nx Regional lymph nodes not assessed 
N0 No metastases in regional lymph nodes 
N1 Metastases in regional lymph nodes 
Distant metastases   
M0 No distant metastases 
M1a Metastases in distant lymph nodes 
M1b Bone metastases 
M1c Other metastases with or without bone disease 
 
 
 
Early carcinomas (pT1b-2) can be treated with curative intention by radical prostatec-
tomy (RP), radiation therapy or androgen deprivation therapy (ADT), each separately 
or in combination. In some cases even active surveillance is possible, which replaces 
the former concept of “watchful waiting” – active therapy is initiated as soon as evi-
dence of progression appears, considering the fact that not all PCA detected by 
screening methods are clinically significant. Selection of the most appropriate ap-
proach depends on the general medical condition of the patient, Gleason score, clini-
cal staging, treatment-related side effects, estimated outcome with alternative treat-
ment etc. 
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First line treatment in metastatic PCA is ADT, leading to reduction of pain in 80-90% 
and responses in serum PSA and size of metastases with moderately prolonged sur-
vival, but remains palliative. 
Locally advanced disease (≥ T3) is most effectively treated by radiation therapy in 
combination with ADT. In locally advanced PCA, only young and otherwise healthy 
men benefit from radical prostatectomy – especially with PSA <10 ng/ml and a low to 
moderate Gleason score. 
 
Unfortunately, long-term ADT often results in androgen-independent growth of tu-
mour cells within 18-24 month with a median survival of 24-30 month (Denis et al., 
1998). From this point on, therapy of PCA is based on aggressive chemotherapeutic 
agents with additional radiotherapy. For a long time, chemotherapy with mitoxantrone 
and a corticosteroid did not have a major beneficial impact after progression to an-
drogen independency. A more advanced docetaxel-based therapy regimen shows 
promising signs of improvement in PSA response rates and quality of life, but re-
mains palliative with a median survival of 20 month (Tannock et al., 2004). 
 
Regarding these significant prognostic and therapeutic differences between early and 
advanced disease, prostate cancer research focuses on three main topics:  
1) The understanding of the genetic mechanisms of PCA development and pro-
gress to advanced state. 
2) The identification of suitable prognostic biomarkers that can distinguish be-
tween significant and insignificant, as well as low and high risk PCA. 
3) The development of pharmacological agents for therapy after progression to 
androgen-independency when conventional cytotoxic regimes fail to succeed.  
 
From a clinical point of view this means (Schlomm et al., 2007): Which patients do 
not require local therapy? Which therapy is the most appropriate one for a particular 
patient? What can be done after progression to androgen independency or when me-
tastases are present? 
Tyrosine kinases (TKs) represent an important link in these fields of PCA research 
regarding their emerging role in various tumour entities. 
   
13 
__________________________________________________________________________________________________________________________________________________________________ 
 
1.2. Tyrosine kinases: general remarks 
TKs represent a family of proteins characterized by their ability to transfer the γ-
phosphate-residue from adenosine triphosphate (ATP) to tyrosine residues on spe-
cific cellular proteins modifying their catalytic or binding properties by phosphorylation 
(Schlessinger, 2000). Thus biochemical signals are initiated which end in modified 
gene transcription or enzyme activities. Three mechanisms for activation of effector 
proteins by receptor tyrosine kinases are: 
1) Activation by membrane translocation 
2) Activation by a conformational change, releasing binding sites or enzymatic 
activity 
3) Activation of enzymatic activity by tyrosine phosphorylation. 
 
TKs play a key role in most types of cancer: They are located at important switch 
points of most cellular signalling pathways and communicate with a complex network 
of signalling molecules that affect proliferation, differentiation, motility, cell death and 
apoptosis (Vlahovic and Crawford, 2003). More than 70% of known oncogenes and 
proto-oncogenes involved in cancer encode tyrosine kinases (Levitzki and Gazit, 
1995).  
Possible ways of oncogenic transformation by tyrosine kinases (Blume-Jensen and 
Hunter, 2001): 
1) retroviral transformation of a TK with proto-oncogene function (common in 
rodent and chicken) 
2) genomic rearrangements (e.g. translocations) to oncogenic fusion proteins 
containing a TK catalytic domain and an unrelated protein with dimerization 
function (e.g. BCR-ABL translocation in chronic myeloid leukemia) 
3) gain-of-function mutations/small deletions (e.g. c-kit point mutations in gas-
trointestinal stromal tumours) 
4) aberrant TK expression (e.g. EGFR overexpression in non-small-cell lung 
cancer) 
 
Therefore they are in the focus of numerous examinations investigating the molecular 
basis of tumour development and progress. Several examples exist where TKs are 
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directly involved in tumour formation such as in the signalling systems of VEGF, 
EGF, FGF, PDGF, KIT, IGF, ABL and JAK. 
TKs have also been shown to be important pharmacological targets (Shawver et al., 
2002). Broad clinical application is already established, for example, in the therapy of 
non-small cell lung cancer (NSCLC) with the EGFR-inhibitor gefitinib (Iressa®), in 
chronic myeloid leukemia with the bcr/abl-inhibitor imatinib (Glivec®) and in breast 
cancer with the ErbB2-inhibitor trastuzumab (Herceptin®). A phase II-study of 
imatinib in PCA has recently shown positive results, underlining the potential of TK-
inhibitors even in prostate cancer therapy (Rao et al., 2005b; Blackledge, 2003).  
 
Due to its involvement in mitogenic signalling, stringent regulation of TK expression is 
mandatory for maintaining normal cellular functions (Blume-Jensen and Hunter, 
2001). Vice versa, differential expression of tyrosine kinases leads to aberrant growth 
behaviour of cells with the potential of malignant transformation. Consequently, ex-
pression analyses of TKs belong to the most interesting topics in cancer research. 
 
1.3. TKs in prostate cancer 
In PCA, TKs can be regarded under several aspects. This reaches from basic re-
search concerning cancer development and progress to patient-oriented applications, 
e.g. prognostic analyses or pharmacological applications. Several examples of TKs 
contributing to PCA development are described in this section. 
 
A role for TKs could be shown especially for progress to androgen independency of 
PCA (Debes and Tindall, 2004; Feldman and Feldman, 2001): 
One pathway towards androgen independency involves the androgen receptor (AR), 
e.g. AR receptor mutations/overexpression, growth factor/cytokine deregulation or 
alteration of coactivators. AR amplification leads to enhanced receptor signalling, 
while mutations increase the number of ligands that may activate the receptor. Also 
overexpression of TK ligands (e.g. IGF I, EGF) that increase AR coactivators or di-
rectly activate the AR is well known. Furthermore, overexpression of ERBB2 or 
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EGFR can activate AR-dependent genes in absence of AR ligands, but not without 
AR (Sugita et al., 2004; Di Lorenzo et al., 2002). 
Another pathway completely bypasses the androgen receptor by deregulation of 
apoptotic genes, e.g. decreased PTEN expression. This leads to inhibition of apop-
tosis via increased Akt/Bcl-2 activity. Lately, loss of PTEN expression could be 
shown to increase TK activity of JNK, which is highly correlated with Akt activity in 
prostate cancer (Vivanco et al., 2007). 
In 2007, interesting interactions between AR and the hepatocyte growth factor recep-
tor MET could be demonstrated in PCA (Verras et al., 2007). This TK was shown to 
be repressed by AR signalling. Consequently, inhibiton of AR leads to enhanced 
MET activity with subsequent growth stimulation. Future analyses will have to show, 
if MET inhibition simultaneously with ADT would lead to an additional antitumour ef-
fect.  
 
Further single TK are known to be involved in prostate carcinogenesis: Tyk2 (a 
member of the JAK family) expression and signalling seems to be associated with 
PCA invasiveness (Ide et al., 2007). BMX and ETK nonreceptor TK are activated by 
PI3 kinase, EGFR and ERBB3, stimulating growth of PCA cell lines (Jiang et al., 
2007) and inducing intraepithelial neoplasia in mouse (Dai et al., 2006). Fer, a nonre-
ceptor TK, was shown to be required for proliferation in PCA cell lines, while inhibi-
tion using RNA interference impedes cell-cycle progression (Pasder et al., 2006).  
The role of TKs for carcinogenesis is further evidenced by the finding, that a down-
regulation of Sef, an inhibitor of TK signalling, is associated with high grade and me-
tastatic PCA (Darby et al., 2006). This was confirmed very recently for several human 
carcinomas  (Zisman-Rozen et al., 2007). 
Numerous articles more can be found reporting the role of single TK in prostate car-
cinogenesis, while systematic surveys of TK expression are very limited: 
First attempts to a systematic TK expression profile have been published in 1996 
(Robinson et al., 1996). With degenerated primers, cDNA of 30 human tyrosine 
kinases could be amplified. Members of EGFR family were analysed semiquanita-
tively by EGFR-family-specific primers and gel electrophoresis. Almost all analysed 
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tumour specimen expressed EGFR, ERBB2 and ERBB3, while ERBB4 was not ex-
pressed in any prostate specimen. 
Microarray studies do not provide detailed information about TK expression, because 
they have to focus on a set of genes mostly selected by cluster analysis. In this set-
ting most kinases are excluded from a precise analysis/presentation because of sta-
tistical reasons. As an example, only two TK (EPHB2 and NTRK2) are found among 
106 differentially expressed genes identified by an elaborate microarray study (hor-
mone-refractory PCA vs. hormone-sensitive PCA; (Tamura et al., 2007).  
 
Motivated by reports about an EGFR overexpression in PCA, trials with EGFR inhibi-
tors have been initiated. Results of several phase II studies were published very re-
cently: A phase II study demonstrated that gefitinib (Iressa®) has no single-agent 
activity in nonmetastatic PCA, while tolerability was very favourable (Small et al., 
2007). Another phase II trial evaluating docetaxel in combination with gefitinib failed 
to show an additional effect of gefitinib to docetaxel alone (Salzberg et al., 2007). 
Similar results were obtained in a phase II trial of docetaxel and the EGFR inhibitor 
erlotinib (Tarceva®) as therapy for elderly patients with androgen-independent pros-
tate cancer (Gross et al., 2007).  
Current studies are evaluating associations between receptor gene mutations and 
response to EGFR inhibition, because strong correlations between EGFR mutations 
and gefitinib response have been shown for NSCLC (Lynch et al., 2004; Taron et al., 
2005). A first report indicates similar phenomens in PCA (Curigliano et al., 2007). 
For trastuzumab (Herceptin®), an ERBB2 inhibitor, antitumour activity could be 
shown in vitro (Agus et al., 1999), but not in early clinical studies (Morris et al., 2002). 
Several preclinical and clinical data suggest synergistic effects for inhibiting multiple 
members of the HER-kinase axis (Gross et al., 2005). 
Another signalling system involves the PDGFR, which is reported to be overex-
pressed in PCA. Details about the application of the PDGFR inhibitor imatinib are 
explained below, as the targeted receptor is not yet definitive. Leflunomide is another 
PDGFR-targeting agent, which could be shown to have certain antitumour effects in 
clinical studies (Ko et al., 2001). 
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Inhibitors of VEGFR signalling are currently under investigation – first data concern-
ing pharmacokinetics and tolerability have been recently published, but so far without 
clear indicators of tumour response (Ryan et al., 2007). 
 
Taken together, in PCA no single TK with contribution to tumour formation compara-
ble to breast cancer or AML has been identified up to now. Clear prognostic data 
concerning TKs are rare, while the success of TKs as pharmacological targets is still 
unclear.  
 
1.4. Gene expression analysis in cancer research 
1.4.1. General remarks 
While knowledge about structure and sequence of the human genome has been 
completed during the last years, analysis of gene function and regulation is still in 
progress. One of the most interesting topics is the examination of gene expression, 
as this is the first step towards biological activity of a gene product. Especially 
changes in mRNA production often, but not always, correlate with altered protein 
function. 
Different methods are used for quantification of gene expression. Northern Blotting of 
reverse transcribed RNA only provides semiquantitative results with moderate sensi-
tivity. The more recent microarray technology for cDNA quantification is far more 
sensitive and may analyse many thousands of genes simultaneously, but with mod-
erate accuracy. Real-time PCR of reverse transcribed mRNA achieves the most ac-
curate results, but can handle only a limited number of genes because of the high 
experimental effort.  
Until now, gene expression analyses in the prostate have focussed on one or a few 
single genes or have used microarray technology for generating large expression 
profiles, thereby accepting a reduced accuracy when compared to quantitative real-
time PCR (Welsh et al., 2001; Ernst et al., 2002; Luo et al., 2001). Regarding TKs, 
few have been analysed extensively and knowledge about many of them remains 
incomplete. In this study, an intermediate-scale screening method based on highly 
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reliable real-time PCR was established and combined with commercially available 
immunohistochemistry to investigate TK expression. 
1.4.2. Normalization strategies in real-time PCR 
Recently, the way of normalizing expression data has drawn more and more atten-
tion. Different normalizing strategies have been extensively evaluated (Huggett et al., 
2005a). Therefore, a detailed concept for data analysis and normalization had to be 
developed. 
Absolute quantification of a gene transcript requires standards to compare to and 
therefore implicates a lot of experimental effort. Relative quantification mostly refers 
to housekeeping genes (HKG) to control for the amount of RNA input, varying tran-
scriptional activity of different tissue types or enzymatic efficiencies of quantification 
reactions. These endogenous controls are mainly proteins involved in basal cell me-
tabolism or structural proteins, e.g. for cytoskeleton. Well known examples are glyc-
erine-aldehyde-3-phosphate-dehydrogenase (GAPDH), beta-actin, hypoxanthine-
phosphoribosyltransferase 1 (HPRT1), ubiquitin c (UBC) or 18sRNA. For a long time 
they have been assumed to be expressed at the same level in every type of tissue, 
independent from their tissue origin or malignancy. Recent work could demonstrate 
that this assumption introduces remarkable inaccuracy, especially regarding the 
widely used housekeepers GAPDH, 18sRNA and beta-actin (Glare et al., 2002; 
Goidin et al., 2001; Rondinelli et al., 1997; Thellin et al., 1999; Schmittgen and Zakra-
jsek, 2000). As an example, GAPDH expression could be shown to be increased in 
advanced prostate carcinoma (Rondinelli et al., 1997). Furthermore, stable expres-
sion of one housekeeping gene in one tumour type does not predict a stable expres-
sion in another tumour type (Haller et al., 2004b). 
Therefore, for accurate relative quantification it is inevitable to evaluate housekeep-
ing gene expression in the given setting of tissue type and method of analysis (Tri-
carico et al., 2002; Haller et al., 2004c). Different approaches have been published 
for analysis of housekeeping gene expression stability, respectively for selecting the 
most accurate ones out of a pool of candidates, from which an average normalization 
factor has to be calculated (Andersen et al., 2004c; Pfaffl et al., 2004b; Szabo et al., 
2004; Vandesompele et al., 2002). 
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1.5. Research context & purpose 
After sequencing of the human genome was finished, Robinson et al. created the first 
non-redundant catalogue of human TKs derived from significant sequence homolo-
gies in the kinase domain (Robinson et al., 2000). It comprises 90 TK genes and 5 
pseudogenes: 58 receptor TKs (20 subfamilies) and 32 intracellular non-receptor TKs 
(10 subfamilies). Each subfamily shares a similar kinase domain sequence and in-
tron-exon-structure. In this approach, five kinase sequences were identified for the 
first time: EPHA6, EPHX, AATYK3, SRMS and DKFZp761P1010. Short after begin-
ning of our analyses, another tyrosine kinase called NOK has been described show-
ing significant homologies to the PDGFR/FGFR-family (Liu et al., 2004). 
 
Based on the classification of Robinson, interesting results were obtained recently in 
a real-time PCR study of receptor TK expression in 372 tumour and benign samples 
of different tissue origins without prostate (Muller-Tidow et al., 2004). They revealed 
that there are tissue-specific kinase expression profiles that can differentiate between 
benign and malignant samples. Numbers of expressed tyrosine kinases differed 
widely among different tissue types. While brain tumours expressed 50 of 58 tested 
receptor tyrosine kinases, only 20 TK gene transcripts could be detected in AML 
bone marrow samples. One possible explanation for this phenomenon could be the 
more heterogenous composition of brain tissue, where glial cells, vascular tissue etc. 
account for other TK transcripts than neural tissue alone. AML bone marrow is far 
more homogenous, especially as blasts have been enriched by density centrifugation 
before performing RNA extraction. In AML samples, the expression profile could be 
shown to be associated with patient survival (e.g. FLT3 and RET overexpression are 
associated with poor prognosis). In another study, a series of non-small cell lung 
cancer (NSCLC) has been examined with similar results: Receptor TK expression 
profile was able to predict metastasis and survival in early stage NSCLC (Muller-
Tidow et al., 2005). Methodic disadvantages of these two studies are the use of 
oligo-dT-priming for reverse transcription inducing systematic biases (details below) 
as well as normalization with GAPDH as single housekeeper. 
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In the present study, the mentioned approach of Muller-Tidow et al. is extended from 
receptor TKs to all TKs in the prostate, excluding the five pseudogenes and one re-
ceptor TK gene that shares great homologies with EPH kinases and is not known to 
be expressed in humans.  
A highly standardized protocol for tissue sampling and processing had to be devel-
oped to preserve RNA quality and to allow exact histological characterisation and 
high-quality fresh frozen tissue for research purposes. 
For RNA quantification, the TaqMan® Low Density Array technology (Applied Biosys-
tems, Foster City, CA) should be established in our laboratory, which combines high 
throughput technology and the accuracy of quantitative real-time PCR, thereby clos-
ing the gap between high-scale array technology and conventional real-time PCR. 
First successful applications of this technology have recently been published (An-
tonov et al., 2005; Marionneau et al., 2005; Tenedini et al., 2004; Abruzzo et al., 
2005).  
Unfortunately commercially available software solutions do not consider recent de-
velopments in the emerging field of real-time PCR data analysis (Huggett et al., 
2005b). Therefore an elaborate combination of several software solutions had to be 
compiled for data normalization and processing. 
This aims at the identification of new differentially expressed TK candidate genes in 
prostate carcinoma that have not been investigated up to now. Expression differ-
ences seen in real-time PCR should be confirmed exemplarily by immunohistochem-
istry on protein level. 
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2. MATERIALS AND METHODS 
 
2.1. Prostate Tissue Specimen 
PCA specimens were obtained from 9 patients undergoing radical prostatectomy for 
PCA at the University Hospital of Bonn between August 2004 and February 2005. 
Benign prostate tissue was obtained from 3 patients who underwent radical cystec-
tomy for bladder cancer or prostatectomy because of benign prostatic hyperplasia 
(BPH). All patients gave informed consent for the use of the surgical specimen for 
research. Cases were selected out of ~70 tissue specimen collected for the tumour 
bank of the institute of pathology to represent a broad range of Gleason scores. 
Helpap/WHO-grading correlated well with the Gleason score, indicating morphologic 
unambiguity. No patient received neoadjuvant radiation or androgen ablation therapy. 
For clinicopathological details see Table 2. 
 
 
Table 2: Clinicopathological details of prostate specimen (LN= Lymphatical node, 
SM= surgical margin, SV= seminal vesicle) 
Case 
number 
Gleason Score Helpap Stage LN+ SM SV pre-OP PSA 
PST47 (bladder cancer)      9,68 ng/ml 
PST20 (BPH)      3,95 ng/ml 
PST42 (BPH)        4,75 ng/ml 
PST35 2+2=4 1b pT2c N0 M0 0 - - 8.49 ng/ml 
PST37 2+3=5 2a pT2a N0 M0 0/12 - - 8,7 ng/ml 
PST34 3+2=5 2a pT3b N0 M0 0/12 + + 13.0 ng/ml 
PST52 2+3=5 2a pT2c N0 M0 0/30 - - 8.57 ng/ml 
PST50 3+2=5 1b pT2c N0 M0 0 - - 12.0 ng/ml 
PST49 3+4=7 2a pT2c N0 M0 0/16 + - 8.72 ng/ml 
PST53 3+4=7 3a pT2c N0 M0 0/24 - - 18.8 ng/ml 
PST28 4+4=8 3b pT3b N1 M0 2/29 - + 7.26 ng/ml 
PST18 5+4=9 3b pT3b N0 M0 0 - + 5.9 ng/ml 
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2.2. Tissue Handling 
For maintaining RNA integrity, tissue specimens were immediately chilled on ice and 
processed within 20-30 minutes after intra-operative interruption of the blood supply 
to the prostate. Tissue separation into research and diagnostic specimen was done 
by experienced pathologists. Samples for molecular analyses were embedded in 
O.C.T. Compound (Tissue-Tek, Sakura Finetek, Torrance, CA) and flash-frozen in 
liquid nitrogen.  5µm hematoxylin-eosin (HE) stained cryostat sections were used for 
histological characterisation. The remaining tissue was formalin-fixed and paraffin-
embedded for routine histopathological evaluation including immunohistochemistry 
and Gleason/Helpap scoring by at least two independent experienced pathologists 
(L. Heukamp and P. Kahl). 
For this study, cases were selected that contained at least 70% of epithelial tumour 
tissue in the flash-frozen specimen, which were then stored at -80°C. If sections con-
tained contaminating areas of lower tumour content or benign epithelial cells, these 
were removed by a cold knife in the cryostat. The selected area was cut into 50-
60µm sections and given over to RNA isolation if no remarkable change in macro-
scopic tissue morphology occurred during sectioning. Otherwise another HE-stained 
section was cut for histological confirmation of tissue composition. To ensure a com-
parable epithelial-stroma-ratio, benign specimens were also trimmed to enrich epithe-
lial cells, thus representing >70% of total cells (Examples of histology see Fig. 1:  
PST47 and PST18). 
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Figure 1: Examples of histology: PST47 (benign) ↑  and PST18 (malign) ↓. 
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2.3. Intermittent tests with laser-capture microdissection 
In the beginning we tried to isolate pure epithelial cell populations for RNA extraction 
using laser-capture microdissection (LCM). For this application we used a RNA stabi-
lizing solution according to the manufacturer’s recommendations (RNAlater, Qiagen, 
Hilden, Germany):  Harvested tissues were immediately submerged in RNAlater for 
24h at room temperature, after that tissue was removed from RNAlater and stored at 
-80° until use. 
For laser-capture microdissection frozen tissue was embedded in O.C.T. Compound 
(Tissue-Tek, Sakura Finetek, Torrance, CA). Cryostat sections of 10µm were real-
ized, one was HE-stained for histological evaluation and some were mounted on 
RNAse-free glass slides coated with a 1.35µm polyethylene naphthalene membrane 
(P.A.L.M. Microlaser Technologies, Bernried, Germany) for microdissection. Sections 
were immediately washed in 70% ethanol in DEPC-treated water for 1h. Subsequent 
staining was done in 0,5 % w/v Methyl Green (Fluka, Buchs, Switzerland, 67060) for 
30 sec and thoroughly rinsed with DEPC-treated water. Finally, slides were dipped in 
pure ethanol and dried by incubation at 37°C for 30 min. Microdissection was per-
formed immediately using a PALM Microbeam system (P.A.L.M. Microlaser Tech-
nologies, Bernried, Germany). Selected cells were excised in groups of ~250 cells 
contact-free by the ultraviolet laser beam, catapulted into caps of PCR vials and col-
lected in RNEasy lysis buffer containing β-mercaptoethanol (Qiagen, Hilden, Ger-
many). About 25.000-50.000 cells collected per specimen were proceeded to RNA 
extraction using the RNEasy Micro Kit as described below without further tissue dis-
ruption or homogenisation. (Because of low RNA yield and quality, this microdissec-
tion step was not performed in the final experimental protocol.) 
 
2.4. RNA extraction 
Total cellular RNA was isolated from about 5mg of tissue and DNAse-treated by 
means of the RNeasy Micro Kit (Qiagen, Hilden, Germany). For tissue disruption and 
homogenization a rotor-stator homogenizator (Ultra-Turrax, Ika, Germany) was used 
in RNeasy lysis buffer (Qiagen). The isolation procedure was performed according to 
the manufacturer’s recommendations except for a reduced DNase incubation time of 
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10 min instead of 15 min, which increased the RNA yield by ~10%. RNA was quanti-
fied and quality was assessed by spectrophotometry in Tris-EDTA (TE) buffer to 
achieve quotients in 260/280 nm absorbance >1.95. RNA integrity was ensured by 
ethidium bromide stained agarose gel electrophoresis showing two distinct bands for 
18- and 28s-RNA under UV-light. RNA specimen were aliquotized and stored at         
-80°C. 
 
2.5. Reverse transcription & control PCR 
Isolated total RNA was reverse transcribed with the Omniscript RT Kit (Qiagen, Hil-
den, Germany) as described by the manufacturer with an input of 2µg of total RNA 
per reaction and random-nonamer primers (Operon, Huntsville, AL). We did every 
reverse transcription (RT) in duplicate. After reverse transcription each reaction 
product was separately tested by real-time PCR with a pre-designed GAPDH-primer 
(expression assay Hs99999905_m1, Applied Biosystems, Foster City, CA) to contain 
the same yield of cDNA and to be free of contamination with PCR-inhibitors. Control-
real-time PCR was done in triplicate using 384-well plates with a reaction volume of 
10 µl per well, each containing 0,5 µl of cDNA, 4,5µl RNAse-free water and 5 µl 2x 
TaqMan Universal PCR master-mix (Applied Biosystems, Foster City, CA).  Plates 
were thermal cycled at 50°C for 2 min and 95°C for 10 min, followed by 40 cycles at 
95°C for 15 s, and 60°C for 1 min on an ABI Prism 7900HT instrument (Applied Bio-
systems, Foster City, CA). Ct values were calculated by SDS 2.2 Software (Applied 
Biosystems, Foster City, CA, automatic baseline- and threshold-setting). 
If control reactions did not exceed 1 Ct value in difference, cDNA-duplicates were 
pooled for further analyses.  
 
2.6. Real-Time PCR 
PCR reactions were performed using the TaqMan® Low Density Array technology 
(Applied Biosystems, Foster City, CA), which should be established in our laboratory.  
Arrays with four sets of 96 genes were designed; each reaction was performed in 
duplicate. Primer/probe-sets were selected from a large pool of TaqMan gene ex-
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pression assays and spotted on 384-well cards during fabrication by the manufac-
turer. For assay details see Table 3. Beside the 89 TKs, five putative endogenous 
control genes were included on each set of 96 genes: hypoxanthine-
phosphoribosyltransferase-1 (HPRT1), ubiquitin c (UBC), glucose-6-phosphate-
dehydrogenase (G6PDH), RNA-Polymerase type II and 18sRNA.  
HPRT1 and UBC are well known genes that are reported to be proper controls in a 
variety of experimental settings (de Kok et al., 2005; Haller et al., 2004a; Kim and 
Kim, 2003; Szabo et al., 2004; Foss et al., 1998). G6PDH and RNA Polymerase type 
II are quite new housekeeper candidate genes that are involved in basic cell func-
tions such as pentose phosphate pathway and mRNA synthesis which suggests uni-
form expression (Radonic et al., 2004). 18sRNA had to be analysed despite some 
critical reports concerning its expression stability because of internal quality control 
reasons of the Low Density Array System from Applied Biosystems. 
Additionally, we included quantification of desmin- and CD45-mRNA. Desmin repre-
sents an important marker of stromal content (predominantly smooth muscle) in pros-
tate tissue specimen. CD45-mRNA is expressed in almost every white blood cell and 
should monitor infiltration of specimen by inflammatory cells. 
All amplicons span an exon-exon-junction to achieve mRNA specificity and have a 
two-digit base-pair (bp) length.  
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Table 3: TaqMan-Assay details. 
 
Non-receptor tyrosine kinases   
  gene name alterative gene name 
assay ID        
Applied Biosys-
tems 
Additional information 
1 
ABL family 
ABL1  Hs00245445_m1
v-abl Abelson murine leu-
kemia viral oncogene ho-
molog 1 
2 ARG ABL2 Hs00270858_m1
v-abl Abelson murine leu-
kemia viral oncogene ho-
molog 2 (arg, Abelson-
related gene) 
3 
ACK family 
ACK1  Hs00178648_m1 activated Cdc42-associated kinase 1 
4 TNK1  Hs00177708_m1 tyrosine kinase, non-receptor, 1 
5 
CSK family 
CSK  Hs00177843_m1 c-src tyrosine kinase 
6 MATK  Hs00176738_m1 megakaryocyte-associated tyrosine kinase 
7 
FAK family 
FAK PTK2 Hs00178587_m1 PTK2 protein tyrosine kina-se 2 
8 PYK2 PTK2B Hs00169444_m1 PTK2B protein tyrosine ki-nase 2 beta 
9 
FES family 
FER  Hs00245497_m1
fer (fps/fes related) tyrosine 
kinase (phosphoprotein 
NCP94) 
10 FES  Hs00171375_m1 feline sarcoma oncogene 
11 
FRK family 
BRK/PTK6 PTK6 Hs00178742_m1 protein tyrosine kinase 6 
12 FRK  Hs00176619_m1 fyn-related kinase 
13 SRMS  Hs00365564_m1
src-related kinase lacking C-
terminal regulatory tyrosine 
and N-terminal myristylation 
sites 
14 
JAK family 
JAK1  Hs00233820_m1 Janus kinase 1 (a protein tyrosine kinase) 
15 JAK2  Hs00234567_m1 Janus kinase 2 (a protein tyrosine kinase) 
16 JAK3  Hs00169663_m1 Janus kinase 3 (a protein tyrosine kinase) 
17 TYK2  Hs00177464_m1 tyrosine kinase 2 
18 
SRC-A 
family 
FGR  Hs00178340_m1
Gardner-Rasheed feline 
sarcoma viral (v-fgr) onco-
gene homolog 
19 FYN  Hs00176628_m1 FYN oncogene related to SRC, FGR, YES 
20 SRC  Hs00178494_m1
v-src sarcoma (Schmidt-
Ruppin A-2) viral oncogene 
homolog (avian) 
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21 YES1  Hs00736972_m1 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 
22 
SRC-B 
family 
BLK  Hs00176441_m1 B lymphoid tyrosine kinase 
23 HCK  Hs00176654_m1 hemopoietic cell kinase 
24 LCK  Hs00178427_m1 lymphocyte-specific protein tyrosine kinase 
25 LYN  Hs00176719_m1
v-yes-1 Yamaguchi sarcoma 
viral related oncogene ho-
molog 
26 
TEC family 
BMX  Hs00176455_m1 BMX non-receptor tyrosine kinase 
27 BTK  Hs00163761_m1 Bruton agammaglobulinemia tyrosine kinase 
28 ITK  Hs00178571_m1 IL2-inducible T-cell kinase 
29 TEC  Hs00177389_m1 tec protein tyrosine kinase 
30 TXK  Hs00177433_m1 TXK tyrosine kinase 
31 
SYK family 
SYK  Hs00177369_m1 spleen tyrosine kinase 
32 ZAP70  Hs00277148_m1 zeta-chain (TCR) associated protein kinase 70kDa 
      
 
Receptor tyrosine kinases   
  
33 
ALK family 
ALK  Hs00608289_m1 anaplastic lymphoma kinase (Ki-1) 
34 LTK  Hs00176712_m1 leukocyte tyrosine kinase 
35 
AXL family 
AXL  Hs00242357_m1 AXL receptor tyrosine kina-se 
36 MER MERTK Hs00179024_m1 c-mer proto-oncogene tyro-sine kinase 
37 TYRO3  Hs00170723_m1 TYRO3 protein tyrosine kinase 
38 DDR  
family 
DDR1  Hs00233612_m1 discoidin domain receptor family, member 1 
39 DDR2  Hs00178815_m1 discoidin domain receptor family, member 2 
40 
EGFR 
family 
EGFR/ERBB1  Hs00193306_m1
epidermal growth factor 
receptor (erythroblastic leu-
kemia viral (v-erb-b) onco-
gene homolog, avian) 
41 ERBB2  Hs00170433_m1
v-erb-b2 erythroblastic leu-
kemia viral oncogene ho-
molog 2, neuro/glioblastoma 
derived oncogene homolog 
(avian) 
42 ERBB3  Hs00176538_m1
v-erb-b2 erythroblastic leu-
kemia viral oncogene ho-
molog 3 (avian) 
43 ERBB4  Hs00171783_m1
v-erb-a erythroblastic leu-
kemia viral oncogene ho-
molog 4 (avian) 
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44 
EPH family 
EPHA1  Hs00178313_m1 EPHA1 
45 EPHA2  Hs00171656_m1 EPHA2 
46 EPHA3  Hs00178327_m1 EPHA3 
47 EPHA4  Hs00177874_m1 EPHA4 
48 EPHA5  Hs00300724_m1 EPHA5 
49 EPHA6 DKFZp434C1418 Hs00297133_m1 EPHA6 
50 EPHA7  Hs00177891_m1 EPHA7 
51 EPHA8  Hs00184126_m1 EPHA8 
52 EPHB1  Hs00174725_m1 EPHB1 
53 EPHB2  Hs00362096_m1 EPHB2 
54 EPHB3  Hs00177903_m1 EPHB3 
55 EPHB4  Hs00174752_m1 EPHB4 
56 EPHB6  Hs00270052_m1 EPHB6 
57 
FGFR 
family 
FGFR1  Hs00241111_m1
fibroblast growth factor re-
ceptor 1 (fms-related tyro-
sine kinase 2, Pfeiffer syn-
drome) 
58 FGFR2  Hs00256527_m1
fibroblast growth factor re-
ceptor 2 (bacteria-expressed 
kinase, keratinocyte growth 
factor receptor, craniofacial 
dysostosis 1, Crouzon syn-
drome, Pfeiffer syndrome, 
Jackson-Weiss syndrome) 
59 FGFR3  Hs00179829_m1
fibroblast growth factor re-
ceptor 3 (achondroplasia, 
thanatophoric dwarfism) 
60 FGFR4  Hs00242558_m1 fibroblast growth factor re-ceptor 4 
61 
INSR  
family 
IGF1R  Hs00609566_m1 insulin-like growth factor 1 receptor 
62 INSR  Hs00169631_m1 insulin receptor 
63 INSRR  Hs00299816_m1 insulin receptor-related re-ceptor 
64 
MET  
family 
MET  Hs00179845_m1 hepatocyte growth factor receptor 
65 RON MST1R Hs00234013_m1
macrophage stimulating 1 
receptor (c-met-related tyro-
sine kinase) 
66 MUSK family MUSK  Hs00171797_m1
muscle, skeletal, receptor 
tyrosine kinase 
67 
PDGFR 
family 
CSF1R  Hs00234617_m1
colony stimulating factor 1 
receptor, formerly 
McDonough feline sarcoma 
viral (v-fms) oncogene ho-
molog 
68 FLT3  Hs00174690_m1 fms-related tyrosine kinase 3 
69 KIT  Hs00174029_m1
v-kit Hardy-Zuckerman 4 
feline sarcoma viral onco-
gene homolog 
70 PDGFRA  Hs00183486_m1 platelet-derived growth fac-tor receptor alpha  
71 PDGFRB  Hs00182163_m1 platelet-derived growth fac-tor receptor beta  
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72 PTK7  family PTK7  Hs00177173_m1
PTK7 protein tyrosine kina-
se 7 
73 RET family RET  Hs00240887_m1
ret proto-oncogene (multiple 
endocrine neoplasia and 
medullary thyroid carcinoma 
1, Hirschsprung disease) 
74 ROR  
family 
ROR1  Hs00178178_m1 receptor tyrosine kinase-like orphan receptor 1 
75 ROR2  Hs00171695_m1 receptor tyrosine kinase-like orphan receptor 2 
76 ROS  family ROS1  Hs00177228_m1
v-ros UR2 sarcoma virus 
oncogene homolog 1 (avian)
77 RYK family RYK  Hs00243196_m1 RYK receptor-like tyrosine kinase 
78 
TIE family 
TEK  Hs00176096_m1
TEK tyrosine kinase, endo-
thelial (venous malforma-
tions, multiple cutaneous 
and mucosal) 
79 TIE  Hs00178500_m1
tyrosine kinase with immu-
noglobulin and epidermal 
growth factor homology 
domains 
80 
TRK family 
NTRK1  Hs00176787_m1 neurotrophic tyrosine kinase, receptor, type 1 
81 NTRK2  Hs00178811_m1 neurotrophic tyrosine kinase, receptor, type 2 
82 NTRK3  Hs00176797_m1 neurotrophic tyrosine kinase, receptor, type 3 
83 
VEGFR 
family 
VEGFR1 FLT1 Hs00176573_m1
fms-related tyrosine kinase 
1 (vascular endothelial 
growth factor/vascular per-
meability factor receptor) 
84 VEGFR2 KDR Hs00176676_m1
kinase insert domain recep-
tor (a type III receptor tyro-
sine kinase) 
85 VEGFR3 FLT4 Hs00176607_m1 fms-related tyrosine kinase 4 
86 
AATYK 
family 
AATYK AATK Hs00185425_m1 apoptosis-associated tyrosi-ne kinase 
87 AATYK2 LMTK2 Hs00208698_m1 lemur tyrosine kinase 2 
88 AATYK3 LMTK3 Hs00287418_m1 lemur tyrosine kinase 3 
89 Uncharac-terized DKFZp761P1010  Hs00218290_m1
hypothetical protein 
DKFZp434C1418 
 
Housekeeper/control genes 
   
90 
House-
keeping 
genes 
G6PDH   Hs00166169_m1 glucose-6-phosphate dehyd-rogenase 
91 HRPT1   Hs99999909_m1
hypoxanthine phosphoribo-
syltransferase 1 (Lesch-
Nyhan syndrome) 
92 UBC   Hs00824723_m1 ubiquitin C 
93 18S-rRNA   Hs99999901_s1   
94 RP2 POLR2A Hs00172187_m1
polymerase (RNA) II (DNA 
directed) polypeptide A, 
220kDa 
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95 Stromal and leuko-
cyte mar-
ker 
CD45 PTPRC Hs00236304_m1 protein tyrosine phos-phatase, receptor type, C 
96 Desmin DES Hs00157258_m1 desmin 
 
 
cDNA was diluted to a final concentration of 8ng/µl and mixed 1:1 with 2x TaqMan 
Universal PCR master-mix (Applied Biosystems). 100µl (containing 400ng of cDNA) 
were loaded into each fill port and distributed through microchannels into the 48 reac-
tion wells per fill port by centrifugation (2x1min, 1200rpm, maximum, up ramp rate 
and down ramp rate 9; Sorvall Legend RT centrifuge, Kendro Scientific, Asheville, 
NC, USA; Sorvall/Heraeus Custom Buckets, Applied Biosystems). Subsequent seal-
ing of the microchannels prevented cross-contamination during PCR (for internal 
structure of Low Density Arrays see Fig. 2).  
 
 
 
Fig. 2:  Low Density Array, internal structure (taken from Applied Biosystems 7900HT  
Micro Fluidic Card Getting Started Guide). 
 
 
 
 
Each reaction was performed in duplicate. The arrays were thermal cycled at 50°C 
for 2 min and 94.5°C for 10 min, followed by 40 cycles at 97°C for 30 s, and 59.7°C 
for 1 min on an ABI Prism 7900HT instrument (Applied Biosystems, Foster City, CA). 
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2.7. Data processing and statistics 
Absolute Ct values were calculated using SDS 2.2 Software (Applied Biosystems, 
automatic baseline- and threshold-setting) and transferred into the qBase-software 
(Hellemans et al., 2007) for further analysis and normalization. 
Putative housekeeping genes were evaluated for expression stability using the Ge-
Norm-software (Vandesompele et al., 2002). Briefly, this software calculates a gene-
stability measure for each putative housekeeping gene on the basis of non-
normalized expression levels. It assumes that expression ratios of two ideal house-
keeping genes in two different samples are identical. Consequently, varying expres-
sion ratios of two realistic housekeeping genes to each other in several samples indi-
cate a reduced expression stability of one of the two genes. GeNorm generates a 
ranking of the analysed housekeeping genes from the average pairwise variation of a 
particular housekeeping gene with all other putative candidates.  
Additionally, two other software tools (NormFinder (Andersen et al., 2004b) and 
BestKeeper (Pfaffl et al., 2004c)) were used for confirmation of the GeNorm results.  
 
In qBase, replicates with differences >0.75 Ct values were defined as replicate errors 
and excluded from further analysis. If more than 2 samples per gene contained repli-
cate errors or no amplification, this gene was excluded from further processing. Cal-
culations were done assuming an amplification efficiency of 1.95, which represents 
the tested amplification efficiency of pre-designed TaqMan-assays (1.9-2.0, Applied 
Biosystems, personal communication). Data normalization was performed with the 
geometric mean of RNA-Polymerase II and G6PDH expression using the delta-delta 
Ct method (Livak and Schmittgen, 2001). The benign calibrator sample PST 47 was 
set to gauge 1, expression of other samples is given relatively to PST47. 
Statistical analysis was performed with SPSS 13.0 for Windows (SPSS Inc., Chicago, 
IL, USA). Expression differences between benign and malignant tissue were tested 
for significance with the Mann-Whitney U test. The level of significance was set to 
p<0.05. Calculation of the mean expression differences between groups was derived 
from the geometric mean within the group and given as PCA/BPH ratio. 
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2.8. Immunohistochemistry 
Immunohistochemical stainings were performed by the routine immunohistochemical 
laboratory of the Institute of Pathology as described previously (Heukamp et al., 
2006).  
For FGFR2, 5 µm sections of formalin fixed paraffin-embedded material were placed 
in 200 ml of target retrieval solution (pH 6,0, Envision Plus Detection Kit; Dako, Glos-
trup, Denmark)  for 20 min at 100 °C after microwave pre-treatment. They were 
cooled down for 20 min before quenching with 3% H2O2 for 5 min. Incubation with 
primary antibody against FGFR2 (1:75, Santa Cruz Biotechnology, Santa Cruz, Cali-
fornia, USA, Catalogue-Nr. sc-122) was done in a Dako Autostainer (Dako Cytoma-
tion, Glostrup, Denmark). Slides were developed with EnVisionTM (Dako). 
ABL2 stainings were done on cryostat sections of fresh frozen material using anti-
bodies in 1:50 dilution with microwave pre-treatment following the same protocol as 
described above (AP7695a; Abgent, San Diego, CA, USA) 
Other staining assays were evaluated with other commercially available antibodies 
against FGFR4, NTRK1, NTRK3, and ROR2 (all Abgent, San Diego, CA, USA) using 
cryostat and paraffin-embedded material with systematically varied staining protocols 
(incubation time, fresh-frozen or paraffin embedded tissue, antibody dilution factor, 
microwave pretreatment). 
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3. RESULTS 
 
3.1. RNA-isolation 
RNA-isolation from fresh-frozen specimen yielded adequate amounts of high quality 
RNA. RNA integrity was confirmed with agarose gel electrophoresis, which showed 
two distinct bands (18sRNA and 28sRNA) for all samples without any signs of degra-
dation (Figure 3). As indicator for RNA purity, 260/280 nm absorbance ratios were 
determined by spectrophotometry (Table 4). 
 
 
Figure 3:  Agarose gel electrophoresis for quality control of RNA integrity 
 
 
 
Table 4:  Spectrophotometric 260/280 nm absorbance quotients for quality control of 
RNA 
 260/280 nm absorbance ratio 
PST 35 2,06 
PST 37 2,12 
PST 52 2,07 
PST 28 2,05 
PST 34 2,06 
PST 50 2,5 
PST 49 2,43 
PST 18 2,07 
PST 20 2,05 
PST 47 2,12 
PST 53 2,13 
PST 42 2,00 
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3.2. Intermittent tests with laser-capture microdissection 
Unfortunately, attempts to isolate epithelial cells by LCM resulted in RNA yields that 
were ~20-fold below the required amount. RNA quality control showed significant 
signs of RNA degradation and contaminants in agarose gel electrophoresis and 
spectrophotometry, even using RNA stabilizing solutions (data not shown). 
Consequently, we used microdissection by a cold knife instead of LCM to enrich 
epithelial cells. 
 
 
3.3. Real-time PCR 
The TaqMan Low Density Arrays showed highly reproducible results. Replicate de-
viations of >0.75 Ct values were detected in only ~5% of 2304 PCR reactions, the 
rest showed an average standard error of the mean of 0.08 Ct values. Most TK 
genes were detected in prostate tissue, only LTK and SMRS are presumably not ex-
pressed. RYK could not be amplified because of an incorrect primer concentration 
spotted on the arrays during production (information provided by manufacturer).  
Analysis of marker genes for fibromuscular stroma (i.e. desmin) showed a minor, but 
insignificant, tendency towards underexpression in tumour tissue (mean factor 0,46, 
p=0,1). The marker for leukocytes (CD45) did not show expression differences be-
tween the two groups (mean factor 0,91, p=1,0), excluding inflammatory cells to ac-
count for systematic expression differences. This suggests adequate tissue compa-
rability of tumour and benign specimens. 
Interestingly, analysis of housekeeping gene expression by GeNorm-Software (Van-
desompele et al., 2002) underlined the necessity to careful examination of genes for 
normalization. Especially the widely used 18sRNA showed remarkable expression 
differences between tissue specimen, while a geometric mean of G6PDH and RNA-
Polymerase type II provided the most reasonable results (for results of GeNorm 
analysis see Table 5). Further analyses using other software solutions (Pfaffl et al., 
2004a; Andersen et al., 2004a) confirmed these results. 
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Table 5: Expression stability of housekeeping genes – results of GeNorm-analysis. 
The smallest M-value represents the most stable expressed housekeeping gene. 
 G6PDH RNA-Polymerase II HPRT1 UBC 18sRNA 
M-value 1.044 1.084 1.151 1.266 2.648 
Ranking 1 2 3 4 5 
 
We identified a group of six TKs those expression levels were markedly (i.e. >3-fold) 
dysregulated in cancer specimens, namely ABL2, FGFR2, FGFR4, NTRK1, NTRK3, 
ROR2 (Table 6 A).  
Further genes that expressed a significant but only 2- to 3-fold difference included 
receptor TKs such as EGFR, VEGFR2 and EPHA3 (Table 6 B) known to be engaged 
in tumourigenesis. In these cases exact validation of experimental data in further 
studies is mandatory. 
 
Table 6: Tyrosine kinase candidate genes with significant (p < 0.05) expression dif-
ferences in BPH and PCA.  A) > 3-fold; B) > 2-fold but < 3-fold. 
A ABL2 FGFR2 FGFR4 NTRK1 NTRK3 ROR2 
Mean expres-
sion ratio ma-
lign/benign 
3.393 / 1 1 / 3.461 1 / 4.589 1 / 4.378 1 / 6.037 1 / 3.765 
Exact signifi-
cance p=0.012 p=0.018 p=0.018 p=0.012 p=0.012 p=0.009 
 
 
Correlations with Gleason Score or pathological staging were not tested for signifi-
cance because of the small number of cases. Expression differences below 3-fold 
were excluded as prostate tissue composition remains slightly variable regarding its 
epithelium/stroma ratio despite careful selection and preparation of tissue specimens. 
Expression data of all examined genes are shown together in Figure 4 and Table 7. 
B VEGFR2 KIT EGFR EPHA3 FES TYRO3 
Mean expres-
sion ratio ma-
lign/benign 
1 / 2.566 1 / 2.569 1 / 2.085 1 / 2.373 1 / 2.439 1 / 2.372 
Exact signifi-
cance p=0.009 p=0.009 p=0.009 p=0.036 p=0.009 p=0.009 
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Figure 4: Expression data of all samples and genes, PST47 was set to 1 (calibrator 
sample), all other samples are given relative to PST47 
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Table 7:  Expression ratios of all examined tyrosine kinases in alphabetical order 
(malign/benign). Exclusion of samples was due to replicate errors. Candidate genes 
are marked in grey. 
Gene 
name 
Mean expression 
ratio malign/benign 
Exact  
significance 
Gene 
name 
Mean expression 
ratio malign/benign 
Exact  
significance 
AATK 1 / 2.275 0.085 INSR 1 / 1.541 0.1 
ABL1 1 / 1.211 0.1 INSRR excluded  
ABL2 3,393 / 1 0.012 ITK excluded  
ACK1 1 / 1.164 0.6 JAK1 1 / 1.219 0.6 
ALK excluded  JAK2 1 / 1.332 0.482 
AXL 1 / 1.091 0.727 JAK3 1 / 1.102 0.864 
BLK 1 / 1.072 1 KDR 1 / 2.566 0.009 
BMX 1 / 1.163 0.921 KIT 1 / 2.569 0.009 
BTK 1 / 1.326 0.373 LCK 1 / 1.009 1 
CSF1R 1 / 1.577 0.133 LMTK2 1.297 / 1 0.373 
CSK 1 / 1.092 0.667 LMTK3 excluded  
DDR1 1,088 / 1 0.482 LTK excluded  
DDR2 1 / 1.998 0.1 LYN 1.251 / 1 0.6 
DES 1 / 2.139 0.1 MATK 1.503 / 1 0.6 
DKFZp434
C1418 1,689 / 1 0.383 MERTK 1 / 1.382 0.282 
EGFR 1 / 2.085 0.009 MET 1 / 1.295 0.727 
EPHA1 1 / 1.099 0.727 MST1R excluded  
EPHA2 1 / 1.511 0.133 MUSK excluded  
EPHA3 1 / 2.373 0.036 NTRK1 1 / 4.378 0.012 
EPHA4 1 / 1.703 0.1 NTRK2 1.096 / 1 0.776 
EPHA5 1 / 2.118 0.376 NTRK3 1 / 6.037 0.012 
EPHA7 1 / 1.657 0.209 PDGFRA 1 / 1.987 0.018 
EPHA8 excluded  PDGFRB 1 / 1.556 0.064 
EPHB1 excluded  PTK2 1 / 1.133 0.373 
EPHB2 1 / 1.371 0.482 PTK2B 1 / 1.325 0.282 
EPHB3 1 / 1.044 0.864 PTK6 1.867 / 1 0.533 
EPHB4 1 / 1.579 0.373 PTK7 1 / 1.199 1 
EPHB6 1 / 1.611 0.209 RET excluded  
ERBB2 1 / 1.150 1 ROR1 1 / 1.873 0.209 
ERBB3 1.896 / 1 0.018 ROR2 1 / 3.765 0.009 
ERBB4 1.092 / 1 0.482 ROS1 excluded  
FER 1 / 1.517 0.1 RYK excluded  
FES 1 / 2.439 0.009 SRC 1 / 1.200 0.282 
FGFR1 1 / 2.091 0.145 SRMS excluded  
FGFR2 1 / 3.461 0.018 STYK1 1 / 1.055 1 
FGFR3 1 / 1.025 1 SYK 1 / 1.214 0.6 
FGFR4 1 / 4.589 0.018 TEC 1.276 / 1 0.282 
FGR 1 / 1.065 1 TEK 1.028 / 1 1 
FLT1 1 / 2.415 0.117 TIE 1 / 1.246 1 
FLT3 1 / 1.237 0.711 TNK1 1 / 1.282 0.282 
FLT4 1 / 2.667 0.064 TXK 1 / 1.084 0.864 
FRK 1.148 / 1 0.727 TYK2 1.092 / 1 0.727 
FYN 1 / 1.544 0.282 TYRO3 1 / 2.372 0.009 
HCK 1 / 1.147 0.727 YES1 1.349 / 1 0.373 
IGF1R 1 / 1.649 0.282 ZAP70 1.550 / 1 0.376 
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3.4. Immunohistochemistry 
Validity of real-time PCR data was confirmed exemplarily by immunohistochemical 
staining of 6 malign and 3 benign prostate tissue samples for FGFR2 and 5 malign / 
3 benign specimens for ABL2. Representative examples of histology are shown in 
Figure 5. It shows that BPH and normal tissue adjacent to the tumour have a low 
ABL2 expression whereas expression is enhanced in tumour specimens. FGFR2 ex-
pression is obviously reduced in malign samples. Exact grading of staining intensity 
with statistical evaluation would require larger sample numbers, so here only a quali-
tative statement can be given regarding up- or downregulation of protein expression. 
Other commercially available antibodies tested against FGFR4, NTRK1, NTRK3, and 
ROR2 did not show stainings of adequate quality and specificity. Numerous varia-
tions in staining procedure have been evaluated using cryostat sections of fresh fro-
zen material as well as formalin-fixed paraffin embedded tissue. Nevertheless, no 
specific staining at all or a high level of background staining was seen (data not 
shown).  
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 Figure 5:  Immunohistochemical verification of ABL2 and FGFR2 expression differ-
ences in prostate carcinoma (200x magnification). 
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4. DISCUSSION 
 
 
In the present study, a fairly simple and highly reproducible protocol for expression 
profiling of all TK genes based on the TaqMan Low Density Array technology was 
developed. The focus was to seek out new candidate TKs with a different expression 
pattern in prostate cancer and benign/BPH tissue. 
 
4.1. Methodic details 
Every experimental step was carefully tested for reproducibility. Tissue sampling and 
processing was performed according to a complex protocol to preserve RNA quality 
and to allow exact histological characterisation and high-quality fresh frozen tissue 
for research purposes. 
The protocol for reverse transcription had to be designed very carefully, as this step 
is reported to introduce most of the experimental variation during real-time PCR ex-
pression analysis (Stahlberg et al., 2004). Every reverse transcription was done in 
duplicate and separately tested for cDNA yield. Furthermore, careful selection of the 
priming strategy of reverse transcription is necessary (Zhang and Byrne, 1999). 
When several or more genes have to be compared in one PCR run, it is inevitable to 
consider the different positions of the amplicons inside the transcripts. The widely 
used method of poly-T-priming induces systematic biases by statistically more fre-
quent spontaneously truncated RNA with increasing distance of the amplicon to the 
poly-A-tale. So expression levels are over- or underestimated depending from the 
position of the amplicons to the poly-A-tale. Although the primer/probe-sets in this 
study have been carefully selected to be located near the poly-A-tale, the usage of 
random primers is able to prevent the described effect.  
Recent works demonstrated higher cDNA yields and quality of longer random prim-
ers in reverse transcription, so random nonamers were used instead of the more 
common hexamers for RT-priming. More recently, a study showed even better re-
sults with random pentadecamers (Stangegaard et al., 2006). 
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Also interpretation of expression analyses in the prostate requires some remarks. As 
a result of its highly heterogenic composition, the stromal contamination of a prostate 
tissue specimen is difficult to avoid.  
With laser-capture microdissection (LCM), single cells or groups of cells are cut from 
a microscopic slide and catapulted into a collection tube by a laser beam under mi-
croscopic control. This sophisticated method allows isolation of well defined cell 
populations for further analyses, but unfortunately does not provide adequate 
amounts of intact RNA for larger-scale screening applications. Recently published 
protocols of linear RNA- or cDNA-amplification before real-time PCR applications are 
also limited in solving this problem, as they are extremely complex and cause sys-
tematic errors and problems in standardization (Wilson et al., 2004).  
Even in this study, initial attempts to establish a protocol for laser-capture microdis-
section failed because of the insufficient yield of RNA, which was about 20-fold below 
the required amount. Additionally, RNA quality parameters in gel electrophoresis and 
spectrophotometry showed significant problems with RNA degradation and contami-
nants that could be avoided only incompletely by a RNA stabilizing solution. 
Consequently, we used “macroscopic” microdissection to enrich epithelial cells and 
accepted slight stromal contaminants that cause minor errors in the expression data 
of epithelial cells. This means that the expression difference assigned to an epithelial 
component in this setup cannot be as exact as in a more homogenous epithelial tis-
sue or cell population. Therefore, if TK genes are differently expressed in epithelial 
tissues a cutoff must be set for defining candidate genes to account for the slightly 
varying epithelium/stroma-ratios.  
In this study, the amount of stroma was monitored simultaneously by the desmin ex-
pression, which showed a non-significant tendency towards underexpression in can-
cerous tissue (factor ~0.5). Therefore we set the cutoff at a minimum of 3-fold differ-
ence for candidate TK genes, whereas expression differences between 2- and 3-fold 
mark TK genes of unclear relevance in PCA. CD45-mRNA expression was without 
any difference between benign and malignant specimens, thus excluding leucocytes 
as a source of systematic errors. 
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Further evidence validating real-time PCR data on protein level was obtained by im-
munohistochemical staining of cryostat sections as well as formalin-fixed and paraf-
fin-embedded tissues for FGFR2 and ABL2 with commercially available antibodies. 
 
Unfortunately, commercially available antibodies that were tested for the other candi-
date TKs did not provide clear and reproducible stains of adequate quality and speci-
ficity. This has to be interpreted predominantly as insufficient antibody quality, be-
cause control stainings of the same specimen provided accurate results (Desmin, 
data not shown). Unfortunately, commercially available antibodies against the men-
tioned proteins are very rare, so antibodies from other manufacturers were not avail-
able. Further immunohistochemical evaluation of these genes with more appropriate 
antibodies will be necessary to make preliminary real-time PCR results definitive. 
Interestingly, the most prominent candidate genes are receptor TKs (FGFR2, 
FGFR4, NTRK1, NTRK3 and ROR2), only ABL2 represents a non-receptor intracel-
lular TK. This suggests that extracellular mediators play a central role in PCA car-
cinogenesis. 
 
4.2. Differentially expressed candidate genes 
4.2.1. FGFR-pathway 
The involvement of this signalling pathway in tumour and PCA emergence is well 
known, with impact on different biological functions including proliferation, differentia-
tion, apoptosis, angiogenesis and motility (Wiedlocha and Sorensen, 2004).  
The FGF signalling system comprises several FGFR-isoforms (FGFR 1-4) and many 
ligands (FGF 1-22), which are capable of activating different downstream signalling 
cascades (e.g. the ras/MAP-kinase pathway, ERK1/ERK2, STAT-signalling, PI3-
kinase/Akt etc.; (Eswarakumar et al., 2005). Interpretation of analyses concerning the 
FGFR signalling system is further complicated by the existence of different receptor 
splice variants (e.g. FGFR1-3 isoforms IIIb and IIIc).  
In our tissue specimens we found a significant underexpression of FGFR2 and 
FGFR4 in PCA. A reduced expression of FGFR2 has been already reported in vari-
ous tumours including PCA where low FGFR2 expression is associated with malig-
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nant progression (Naimi et al., 2002). Restoration of underexpressed FGFR2 in a 
PCA cell line suppresses growth and tumourigenicity (Yasumoto et al., 2004).  
Immunohistochemical staining of FGFR2 shows that it is predominantly localized in 
basal epithelial cells. Absence of these cells in carcinoma may explain the downregu-
lation of FGFR2 expression observed in bulk tissue. 
As FGFR2 underexpression is already well known in PCA, our reproduction of this 
result is a good indicator for validity of our real-time PCR results. 
Underexpression of FGFR4 on the other hand is far less common than for FGFR2. 
Up to now, the role of FGFR4 in carcinogenesis is poorly understood. In thyroid car-
cinoma and pediatric rhabdomyosarcoma, FGFR4 overexpression has been reported 
(St Bernard et al., 2005; Khan et al., 2001). Recent reports show a FGFR4 
Gly388Arg polymorphism that correlates with poor prognosis in lung adenocarcinoma 
and PCA (Spinola et al., 2005a; Wang et al., 2004), but not in breast and colorectal 
cancer (Spinola et al., 2005b). Currently, coherences between expression level, 
polymorphism status and signalling behaviour are yet unknown. Therefore the impor-
tance of our finding that FGFR4 is underexpressed in PCA has to be further clarified.  
 
4.2.2. NTRK-pathway 
The neurotrophin-receptor-kinases (NTRK) comprise three receptors (i.e. NTRK 1, 2, 
3) that bind NGF (nerve growth factor) and influence cell growth, differentiation and 
apoptosis. In neuroblastoma, high NTRK1 expression correlates with favourable out-
come. Stable NTRK1 expression in a neuroblastoma cell line promoted expression of 
apoptotic and angiogenesis-inhibiting genes (Schulte et al., 2005) while low expres-
sion in this tumour entity is associated with a poor outcome. On the other hand con-
stitutive receptor activation was shown for several tumour types (e.g. pediatric spin-
dle cell sarcomas, secretory breast carcinoma) in which a constitutively active ETV6-
NTRK3 fusion protein was detected (Pierotti and Greco, 2006; Lannon and Soren-
sen, 2005). These findings indicate a complex synergistic effect between a low re-
ceptor expression level and the constitutive activation of NTRK signalling in malig-
nant tumour emergence. 
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Comparable to neuroblastoma, our expression data show a ~5-fold lower gene ex-
pression level of NTRK1 and NTRK3 in PCA than in benign/normal tissues, underlin-
ing the importance of NTRK function in prostate carcinogenesis.  
Conversely, therapeutic trials in various cell and animal models with the neurotro-
phin-specific TRK-receptor inhibitor CEP-751 show that this agent induces apoptotic 
death in malignant prostate cells (Weeraratna et al., 2000) and inhibits PCA growth 
independent of androgen sensitivity, metastasis, cell proliferation rate or cell differen-
tiation state (Dionne et al., 1998; Weeraratna et al., 2001). Therefore further studies 
will be necessary to evaluate the diagnostic, prognostic and therapeutic relevance of 
NTRK expression and signalling in PCA. 
Possible signalling pathways involve a neurotrophin/Trk receptor autocrine pathway 
which is a important factor for prostate survival pathways (Pinski et al., 2002; Satoh 
et al., 2001). As mechanism for downregulation, methylation was found to be an im-
portant factor for regulation of NTRK gene transcription: NTRK2 could be shown to 
be highly methylated in prostate cancer, even LNCaP and DU145 PCA cell lines did 
not show NTRK2 expression, while expression could be induced be demethylating 
treatment with 5-Azacytidine (Yamada et al., 2004). In our analyses, underexpression 
of NTRK2 was visible, but in contrast to NTRK1 and 3 it did not reach significance. 
 
4.2.3. ROR2 
ROR2 is an orphan receptor TK that plays a crucial role in developmental morpho-
genesis, particularly of the skeleton and neural systems. Mutations in ROR2 could be 
shown to cause the autosomal-recessive Robinow syndrome (van Bokhoven et al., 
2000) and the dominant brachydactyly type B by altering chondrogenesis via 
SMAD1/5-inhibition and an activating SMAD-independent pathway (Oldridge et al., 
2000; Sammar et al., 2004). Analyses of cultured astrocytes showed a partial co-
localization of ROR2 with microtubules (Paganoni et al., 2004), promoting neurite 
growth and branching patterns (Paganoni and Ferreira, 2005).  
Our results show that ROR2 is 4-fold underexpressed in PCA and suggest a role of 
ROR2 in cellular pathways leading to malignant transformation. Possibly these path-
ways involve Wnt-related signalling which contributes to maintaining self renewal of 
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embryonic stem cells (Kristensen et al., 2005). Billiard et al. observed inhibition of 
canonical Wnt3-signalling by ROR2 (Billiard et al., 2005) while Wnt3a was shown to 
promote PCA cell growth via androgen receptors even in the absence of androgens 
(Verras et al., 2004; Mulholland et al., 2006). Consequently, underexpression of 
ROR2 in PCA may lead to altered Wnt-signalling and androgen-mediated prolifera-
tion, thus enhancing malignancy.  
 
4.2.4. ABL2 
Most important, our results show that ABL2 is overexpressed in PCA on mRNA and 
protein level.  
ABL non-receptor TKs influence cell adhesion, cell-cell-contact and cell migration by 
controlling actin remodelling in development and in response to environmental stim-
uli. Similar to the well-known BCR-ABL1 fusion transcript (constitutively active in 
chronic myeloid leukaemia), a BCR3/ABL2 fusion transcript has recently been re-
ported to play an important role in chronic myeloid leukaemia (CML) (Cong et al., 
2005). In a T-cell acute lymphoblastic leukaemia (T-ALL) cell line as well as in an 
AML cell line, an ETV6-ABL2 fusion transcript has been detected (Griesinger et al., 
2002). These findings suggest that deregulated ABL2 activity has a similar effect on 
cell proliferation as activated ABL1. 
Our finding that ABL2 is (~3.4-fold) overexpressed in PCA is clinically relevant since 
ABL2 function may be effectively inhibited by imatinib (STI-571, Gleevec®) (Wange, 
2004), which has become an important therapeutic agent in different cancer entities 
including CML and gastrointestinal stromal tumours (GIST). First clinical trials with an 
imatinib/docetaxel combination therapy in PCA have shown positive results that were 
previously attributed to the targeting of the PDGF receptor family (Rao et al., 2005a). 
Currently, one phase I trial with an docetaxel/estramustine/imatinib combination ther-
apy had to be closed because of a high incidence of thromboembolic complications 
(Lin et al., 2007). Another phase II study demonstrated a limited PSA response with 
moderate toxicity from an imatinib monotherapy (Bajaj et al., 2007).  
But so far, studies evaluating the PDGF receptor expression immunohistochemically 
have failed to provide an empirical basis for successful PDGF receptor targeting by 
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imatinib in PCA (Hofer et al., 2004). ABL2 overexpression demonstrated in our re-
sults is an adequate explanation for the positive effects of imatinib therapy in PCA 
and shows a presumable molecular background for clinical trials based on this treat-
ment. 
 
4.3. Critical remarks, shortcomings & perspective 
 
Expression data in this study are prevailingly based on real-time PCR data in a fairly 
low number of samples. For extensive statistical analyses – for example correlation 
with gleason score/pathological stage – more specimens would have been neces-
sary. Together with clinical data even the prognostic value of certain expression pat-
terns could have been tested.  
Nevertheless, also a limited number of samples can be adequate in screening appli-
cations for identification of new candidate genes, if they are examined in a stringent 
experimental setup and confirmed by a further method (i.e. immunohistochemistry).  
In the present study, verification on protein level succeeded in the case of FGFR2 
and ABL2. This confirms the validity of the obtained real-time PCR data exemplarily 
for two candidate genes, while the definite proof for single candidates remains to be 
done. Unfortunately, commercially available antibodies for the other genes are rare 
and did not show appropriate staining results, so these candidates have to be re-
garded as preliminary. Further studies will have to confirm the results on protein level 
and for a larger number of samples.  
 
Nevertheless, expression analyses are unreliable indicators of causation. Even 
changes in expression of growth factors is not necessary causal of the malignant 
transformation but can be a collateral phenomenon, because disturbance at any 
point of such a signalling network can lead to a multitude of such changes only pe-
ripherally related to the phenotype (Djakiew, 2000). 
Consequently, expression profiles have to be regarded primarily as descriptive and 
require careful interpretation or further analyses concerning causal mechanisms.  
The identification of causal connections will require functional analyses – for example 
analysis of protein phosphorylation status as indicator of protein activity, experiments 
   
49 
__________________________________________________________________________________________________________________________________________________________________ 
 
with specific TK inhibitors in cell cultures or in vivo, analysis of causal processes 
leading to altered gene expression (promoter methylation, histone acetylation) etc.  
This would give a more comprehensive view on functional relationships in the men-
tioned pathways. 
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5. SUMMARY 
 
TK represent a group of enzymes that play a key role in the development of cancer. 
They act as important relay points affecting proliferation, differentiation, cell motility 
and apoptosis. Consequently, they are the focus of studies investigating the molecu-
lar basis of tumour development and progress. Also broad clinical application of TK 
inhibitors is already established for numerous tumour entities (e.g. in non-small cell 
lung cancer with the EGFR-inhibitor gefitinib, in chronic myeloid leukemia with the 
bcr/abl-inhibitor imatinib and in breast cancer with the ErbB2-inhibitor trastuzumab). 
In the present study, a complete gene expression profile all known TK in PCA was 
obtained for the first time. Expression of 89 TK was quantified in 9 malign and 3 be-
nign specimens using real-time PCR technology. 
A highly reproducible protocol was developed for tissue sampling and processing, 
RNA isolation, cDNA synthesis and real-time PCR analysis. Expression data was 
processed using a combination of different software solutions to take on the recent 
developments of normalization and statistics. 
Six TK genes were identified with a significant increase (ABL2: +3.46-fold) or de-
crease (FGFR2: -3.46-fold, FGFR4: -4.59-fold, NTRK1: -4.38-fold, NTRK3: -6.04-fold, 
ROR2: -3.765-fold; p=0,009-0,018) in gene expression. Commercially available anti-
bodies confirmed our data immunohistochemically for FGFR2 and ABL2. 
Especially ABL2 overexpression in prostate cancer is a finding of clinical relevance, 
as it provides a rational background for the application of imatinib in prostate cancer.  
Further studies elucidating protein function or expression in larger cohorts will clarify 
the prognostic value of the obtained expression data. 
The results underline that a real-time PCR all-TK expression assay is a powerful 
screening instrument for identification of deregulated pathways in cancer develop-
ment. It provides important insights into tumour biology that may contribute to better 
diagnostic and prognostic tests as well as more rational therapeutic decision making 
in the therapy of PCA. 
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